Back to Journals » International Journal of Nanomedicine » Volume 17

Biodegradable Materials with Disulfide-Bridged-Framework Confine Photosensitizers for Enhanced Photo-Immunotherapy [Corrigendum]

Authors Li D, Chen F, Cheng C, Li H, Wei X

Received 31 December 2021

Accepted for publication 31 December 2021

Published 20 January 2022 Volume 2022:17 Pages 285—286


Li D, Chen F, Cheng C, Li H, Wei X. Int J Nanomedicine. 2022;16:8323–8334.

On page 8323, the Methods and Results sections have been updated. The revised abstract section should read as follows:

Purpose: Photodynamic therapy (PDT) with spatiotemporal controlled and noninvasive advantages has obtained growing attention in cancer treatment. Nevertheless, PDT still suffers from self-aggregation-induced photosensitizer quenching and reactive oxygen species (ROS) scavenging in cancer cells with abundant glutathione (GSH) pools, leading to insufficient performance.

Methods: Photosensitizer Ce6-loaded nanocarrier (SSNs) with a disulfide-bond-bridged silica framework were developed for enhanced photo-immunotherapy. After studying the GSH-responsive matrix degradation and controlled release of Ce6, the GSH depletion and ROS generation were determined. The tumor killing and immunogenic cell death effects of SSNs@Ce6-mediated phototherapy were investigated in vitro. The tumor accumulation, therapeutic efficacy and safety profile of photo-immunotherapy were also evaluated in vivo.

Results: Such SSNs spatially confine photosensitizer Ce6 in the matrix to prevent self-aggregation. Under the high GSH level of cancer cells, the disulfide-bond-bridged framework was degradable and triggered the exposure of photosensitizers to oxygen, accelerating the ROS generation during PDT. In addition, GSH depletion via the break of the disulfide-bond increased the ROS level, together resulting in efficient tumor killing outcomes with a considerable immunogenic cell death effect in vitro. Importantly, the SSNs@Ce6 accumulated in the tumor site and exhibited enhanced PDT efficacy with low systemic toxicity in vivo. Notably, SSNs@Ce6-miediated PDT completely eradicated 4T1 tumors when combined with the PD-1 checkpoint blockade.

Conclusion: The confinement of photosensitizers in a biodegradable disulfide-bridged-framework provides a promising strategy to unleash the potential of photosensitizers in PDT, especially in combined cancer photo-immunotherapy.

The authors apologize for this error and advise it does not affect the results of the paper.

Read the original article

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.